Bhavana Bhatnagar, DO

Assistant Professor

Organization:

West Virginia University School of Medicine

Department:

Medicine

Classification:

Faculty

Organization:

West Virginia University WVU Cancer Institute

Department:

Section of Hematology / Oncology

Classification:

Clinical Faculty

• DO, Philadelphia College of Osteopathic Medicine, Philadelphia, PA, 2007

Underwood B, Zhao Q, Walker AR, Mims AS, Vasu S, Long M, Haque TZ, Blaser BW, Grieselhuber N, Wall S, Behbehani GK, Blachly JS, Larkin K, Byrd JC, Garzon R, Wang T and Bhatnagar B. Incidence of venous thrombosis after peg-asparaginase in adolescent and young adults with acute lymphoblastic leukemia. Accepted for publication in International Journal of Hematologic Oncology (in press).  

Walker A, Byrd JC, Blachly JS, Bhatnagar B, Mims A, Owrick S, Lin TL, Crosswell HE, Zhang D, Minden MD, Munugalavadla V, Long L, Liu J, Pan Y, Oellerich T, Serve H, Rao AV, Blum WG. Entospletinib in Combination With Induction Chemotherapy in Previously Untreated Acute Myeloid Leukemia: Response and Predictive Significance of HOXA9 and MEIS1. Accepted for publication in Clinical Cancer Research. 

Saygin C, Larkin K, Blachly JS, Orwick S, Ngankeu A, Gregory CT, Phelps MA, Mani S, Walker A, Garzon R, Vasu S, Walsh KJ, Bhatnagar B, Klisovic RB, Grever MR, Marcucci G, Byrd JC, Blum W, Mims AS. A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. Am J Hematol. 2020 Aug 10. doi: 10.1002/ajh.25958. Online ahead of print. PMID: 32777116  

Koenig KL, Sahasrabudhe KD, Sigmund AM, Bhatnagar B. AML with Myelodysplasia-Related Changes: Development, Challenges, and Treatment Advances. Genes (Basel). 2020 Jul 24;11(8):E845. PMID: 32722092. 

Lockwood BJ, Ntukidem OL, Ehrman SE, Schnell PM, Klemanski DL, Bhatnagar B, Lustberg M. Palliative Care Referral Patterns for Adolescent and Young Adult Patients at a Comprehensive Cancer Center. J Adolesc Young Adult Oncol. 2020 Jul 20. Online ahead of print. PMID: 32706607.  

Liva SG, Coss CC, Wang J, Blum W, Klisovic R, Bhatnagar B, Walsh K, Geyer S, Zhao Q, Garzon R, Marcucci G, Phelps MA, Walker AR. Phase I study of AR-42 and decitabine in acute myeloid leukemia. Leuk Lymphoma. 2020 Jun;61(6):1484-1492. doi: 10.1080/10428194.2020.1719095. Epub 2020 Feb 8. PMID: 32037935.  

Jain N, Stock W, Zeidan A, Atallah E, McCloskey J, Heffner L, Tomlinson B, Bhatnagar B, Feingold J, Ungar D, Chao G, Zhang X, Havenith K, Wieduwilt M J. Loncastuximab Tesirine, an Antibody Drug Conjugate, in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia. Blood Adv. 2020 Feb 11;4(3):449-457. PMCID: PMC7013258.  

Bhatnagar B, Zhao Q, Mims AS, Vasu S, Behbehani GK, Larkin K, Blachly JS, Blum W, Klisovic RB, Ruppert AS, Orwick S, Oakes C, Ranganathan P, Byrd JC, Walker AR, Garzon R. Selinexor in combination with decitabine in patients with acute myeloid leukemia: results from a phase 1 study. Leuk Lymphoma. 2020 Feb;61(2):387-396. PMID: 31545113  

Saygin C, Grieselhuber N, Blachly J, Byrd J, Vasu S, Larkin K, Behbehani G, Long M, Walker A, Bhatnagar B, Mims A. Outcomes of the cyclophosphamide, vincristine, prednisone (CVP) +/- rituximab (R-CVP) regimen in older patients with newly diagnosed Ph- acute lymphoblastic leukemia. Leuk Res. 2020 Feb;89:106297. Epub 2020 Jan 7. PMID: 31935625
 

Bertha A. Bouroncle Distinguished Faculty Teaching Award 2020
National Institutes of Health Loan Repayment Award 2019
Huntington Bank & Pelotonia Honor a Doctor Awards Dinner 2019
National Institutes of Health Loan Repayment Award 2017
Early Career Women Faculty Leadership Development Seminar, American Association of Medical Colleges 2017
Alliance for Clinical Trials in Oncology Young Investigator Committee 2017
Patient Satisfaction Award, FY 2016 (Top 10%

Pelotonia IRP Award 2020 – 2022
TP-0903 to treat RAS mutated relapsed/refractory acute myeloid leukemia
PI: Bhavana Bhatnagar, DO & John C. Byrd, MD
Estimated budget: $25,000
DSRP Award FY20- Bhatnagar AML 46050-502807 2020
PI: Bhavana Bhatnagar, DO
Estimated budget: $50,000
Source: M2Gen Corp/H. Lee Moffitt Cancer Center 2019 – 2021
ORIEN NOVA IIP: The impact of donor gamma delta T-cell reconstitution and expression of leukemic cell ligands on immune escape and relapse of AML after allogeneic hematopoietic cell transplantation
PI: Bhavana Bhatnagar, DO
Estimated Budget: $250,000
Teen Cancer America Charitable Grant 2019 – 2021
PI: Bhavana Bhatnagar, DO
Estimated Budget: $467,540
Leukemia Research Program 2019-2020
Using Next-Generation sequencing to predict outcomes of patients with myelodysplastic syndromes and acute myeloid leukemia
PI: Bhavana Bhatnagar, DO
Estimated Budget: $37,000
Principal Investigator:
1. OSU-13182 Phase I Study of Decitabine (Dacogen) and Selinexor (KPT-330) in Acute Myeloid Leukemia
Role: Principal Investigator
Status: Closed
Sponsor: Karyopharm Therapeutics
2. OSU-14089 Phase 1 study of Selinexor in combination with Mitoxantrone, Etoposide and Cytarabine in Primary Refractory and Relapsed Acute Myeloid Leukemia
Role: Principal Investigator
Status: Open
Sponsor: Karyopharm Therapeutics
3. OSU-14169 Phase I Study of Pacritinib and Chemotherapy in Patients with Acute Myeloid Leukemia and FLT3 mutations
Role: Principal Investigator
Status: Open
Sponsor: Cell Therapeutics, Inc.
4. OSU-15258 A Phase I, Open-label, Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)
Role: Site Principal Investigator
Status: Open
Sponsor: ADC Therapeutics
Bhavana Bhatnagar, DO
Page 6 of 28
5. OSU-16127 A Phase 3 Openlabel, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation
Role: Site Principal Investigator
Status: Open
Sponsor: Astellas Pharmaceuticals
6. ECOG-E1910 A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-negative B lineage Acute Lymphoblastic Leukemia in Adults
Role: Site Principal Investigator
Status: Open
Sponsor: Eastern Cooperative Oncology Group (ECOG)
7. SWOG-S1318 A Phase II Study of Blinatumomab (NSC-765986) and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients >/= 65 Years of Age with Newly Diagnosed Philadelphia- Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib (NSC-732517), Prednisone and Blinatumomab for Patients >/= 65 Years of Age with Newly Diagnosed Philadelphia- Chromosome Positive (Ph+) ALL
Role: Site Principal Investigator
Status: Open
Sponsor: Southwest Oncology Group (SWOG)
8. OSU-16281 A Phase II Study of MLN0218 (TAK-228) in Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)
Role: Site Principal Investigator
Status: Open
Sponsor: National Cancer Institute (NCI)
9. OSU-17214 A Multicenter, Open-label Treatment Protocol of Gilteritinib (ASP2215) in Patients with FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) with Minimal Residual Disease (MRD)
Role: Site Principal Investigator
Status: Open
Sponsor: Astellas Pharmaceuticals
10. OSU-17278 An Open-Label, Randomized, Phase II Dose-Finding Study of Pacritinib in Patients with Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis Previously Treated with Ruxolitinib
Role: Site Principal Investigator
Status: Open
Sponsor: Cell Therapeutics
11. CALGB-10403 Intergroup Phase II clinical Trial for Adolescents and young adults(<30yrs) in untreated ALL
Role: Principal Investigator
Status: Closed
Sponsor: CALGB
12. OSU-18119 A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) versus IV Decitabine in Subjects with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
Bhavana Bhatnagar, DO
Page 7 of 28
Role: Principal Investigator
Status: Closed
Sponsor: Astex
13. ALLIANCE-A041703 A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-negative CD22-positive B-lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults with Relapsed or Refractory Disease
Role: Principal Investigator
Status: Open
Sponsor: Alliance
14. OSU-18237 Phase 1/2 Study of ASP2215 (Gilteritinib) Combined with Atezolizumab in Patients with Relapsed or Treatment Refractory FLT3 Mutated Acute Myeloid Leukemia (AML)
Role: Principal Investigator
Status: Open
Sponsor: Astellas Pharma
15. OSU-18379 A Phase II Study of TP-0903 in Combination with Chemotherapy and as Monotherapy in Patients with Acute Myeloid Leukemia and FLT3 Mutations
Role: Principal Investigator
Status: Open
Sponsor: OSU-IIT
16. ALLIANCE-A041501 A Phase III Trial To Evaluate The Efficacy Of The Addition Of Inotuzumab Ozogamicin (A Conjugated Anti-Cd22monoclonal Antibody) To Frontline Therapy In Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL
Role: Principal Investigator
Status: Open
Sponsor: Alliance
17. OSU-18140 Randomized Trial of a Collaborative Palliative and Oncology Care Model for Patients with Acute Myeloid Leukemia Role: Principal Investigator
Status: Open
Sponsor: Mass Gen
18. OSU-18185 A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered with Chemotherapy versus Chemotherapy Alone in Patients with Relapsed/Refractory Acute Myeloid Leukemia
Role: Principal Investigator
Status: Open
Sponsor: GlycoMimetics
19. OSU-18239 A Phase 2, Randomized, Biomarker-driven, Clinical Study in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with an Exploratory Arm in Patients with Newly Diagnosed High-Risk AML and Exploratory Arms with Varying Levels of MCL-1 Dependence
Role: Principal Investigator
Status: Open
Sponsor: Tolero
Bhavana Bhatnagar, DO
Page 8 of 28
20. OSU-16004 Mutation patterns in morphologic remission and relapse in patients with acute myeloid leukemia
Role: Principal Investigator
Status: Open
Sponsor: OSU
21. OSU-18324 A retrospective analysis on the incidence, characteristics and risk factors of venous thromboemobli (VTE) in the adolescent and young adult (AYA) acute lymphoblastic leukemia (ALL) cohort receiving pegasparaginase
Role: Principal Investigator
Status: Open
Sponsor: OSU
22. OSU-18387 A Phase Ib/II Study Evaluating the Safety and Efficacy of Idasanutlin in Combination with Cytarabine and Daunorubicin in Patients Newly Diagnosed with Acute Myeloid Leukemia (AML) and The Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission
Role: Principal Investigator
Status: Open
Sponsor: F Hoffman La Roche
23. OSU-18388 The Impact of Donor #947 & #948; T-Cell Reconstitution and Expression of Leukemic Cell Ligands on Immune Escape and Relapse of AML after Allogeneic Hematopoietic Cell Transplantation
Role: Principal Investigator
Status: Open
Sponsor: OSU
24. OSU-19080 Using Next-Generation sequencing to predict outcomes of patients with myelodysplastic syndromes and acute myeloid leukemia
Role: Principal Investigator
Status: Open
Sponsor: OSU
25. OSU-19093 Assessing mechanisms of intrinsic and acquired resistance in acute myeloid leukemia patients with FLT3 mutations treated with gilteritinib
Role: Principal Investigator
Status: Open
Sponsor: OSU

Medical Specialties

• Hematology/Oncology (Cancer)
• Medical Oncology (Cancer)

Board Certifications

• Hematology, American Board of Internal Medicine
• Internal Medicine, American Board of Internal Medicine
• Medical Oncology, American Board of Internal Medicine

Special Training

• Fellowship, Hematology and Medical Oncology
  University of Maryland's Marlene and Stewart Greenbaum Cancer Center, Baltimore, MD, 2013
• Residency, Internship and Residency
  The Cleveland Clinic Foundation, Cleveland, OH, 2010